%0 Journal Article
%T Elevated serum cytokeratin
%A Dao-Ming Chang
%A Der-Wei Hwu
%A Hsien-Chang Lin
%A Kun-Chen Lin
%A Yau-Jiunn Lee
%A Yu-Hung Chang
%J Annals of Clinical Biochemistry
%@ 1758-1001
%D 2019
%R 10.1177/0004563218796259
%X Serum cytokeratin-18 is believed to be a marker of hepatic cell damage. However, few studies have discussed about the serum cytokeratin-18 concentration in type 2 diabetes mellitus patients and investigated its association with non-alcoholic fatty liver disease as well as metabolic biomarkers. Healthy participants and type 2 diabetes mellitus patients were enrolled. Physical and metabolic factors were recorded, and non-alcoholic fatty liver disease was screened by abdominal ultrasound and the fatty liver index. The cytokeratin-18 concentration was detected using two commercially available immunoassay kits (M30 and M65 ELISA kit, Previa AB, Sweden). Overall, 22.8% (29/127) and 35.9% (42/117) of the participants were diagnosed with non-alcoholic fatty liver disease in the non-diabetes mellitus group and type 2 diabetes mellitus group, respectively. In the non-diabetes mellitus group and type 2 diabetes mellitus group, our result showed that participants with non-alcoholic fatty liver disease had a higher serum cytokeratin-18 M30 and cytokeratin-18 M65 concentration as compared with participants without non-alcoholic fatty liver disease. Interestingly, as compared with healthy participants without non-alcoholic fatty liver disease, our result also demonstrated that type 2 diabetes mellitus patients without non-alcoholic fatty liver disease had a higher serum cytokeratin-18 M30 (108.4£¿¡À£¿66.2 vs. 87.1£¿¡À£¿34.6 U/L; P£¿=£¿0.038) and cytokeratin-18 M65 concentration (285.4£¿¡À£¿115.3 vs. 248.5£¿¡À£¿111.3 U/L; P£¿=£¿0.031). The independent relationship between type 2 diabetes mellitus and cytokeratin-18 was further strengthened by the significant positive association between fasting plasma glucose and serum cytokeratin-18 concentration via multivariate regression analyses (cytokeratin-18 M30: ¦Â£¿=£¿0.034, P£¿=£¿0.029; cytokeratin-18 M65: ¦Â£¿=£¿0.044, P£¿=£¿0.002). Independent of non-alcoholic fatty liver disease, our results suggested that the cytokeratin-18 concentration is closely associated with the hyperglycaemic milieu. The association between serum cytokeratin-18 and type 2 diabetes mellitus may be worthy of further investigation
%K Clinical studies
%K diabetes
%K liver disease
%U https://journals.sagepub.com/doi/full/10.1177/0004563218796259